Overall Survival of Primary Intracranial Atypical Teratoid Rhabdoid Tumor Following Multimodal Treatment: A Pooled Analysis of Individual Patient Data.


Journal

Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 01 10 2018
accepted: 13 11 2018
pubmed: 12 12 2018
medline: 23 9 2020
entrez: 12 12 2018
Statut: ppublish

Résumé

No standard treatment protocol to guide the management of the primary central nervous system atypical teratoid rhabdoid tumors (ATRTs). To evaluate the efficacy of GTR (gross total resection), RT (radiotherapy), CCMT (conventional chemotherapy), or intensified chemotherapy (ICMT) and verify the optimal treatment strategy. A total of 501 cases (18 cases from our center and 483 cases from published literature) were eligible for analysis. Clinical characteristics were reviewed, and overall survival (OS) of each combined treatment modality was compared. These prior publication data were processed according to PRISMA guidelines. This study included 265 (52.9%) males and 216 (43.1%) females. The median age of the cohort was 2.2 years with 295 (58.9%) cases younger than 3 years. GTR was achieved in 217 (43.3%) patients. Initial adjuvant CCMT, CCMT plus intrathecal chemotherapy (ITCMT), CCMT plus high-dose chemotherapy (HDCMT), and CCMT plus ITCMT and HDCMT were administered in 228 (45.5%), 78 (15.6%), 55 (11.0%), and 24 (4.8%) patients, respectively. Radiotherapy (RT) was prescribed in 266 (53.1%) patients. Fewer patients younger than 3 years old received RT (21.9% vs 33.0%, p < 0.001, chi-square test). The OS of the entire cohort at 1, 3, and 5 years were 56.6, 35.9, and 30.8%, respectively. After adjusting for age and sex, GTR (HR 0.630; p < 0.001), RT (HR = 0.295; p < 0.001), CCMT (HR = 0.382; p < 0.001), and ICMT (HR = 0.209; p < 0.001) were independent prognostic factors. The 3-year OS of surgery alone, surgery plus CCMT, surgery plus RT, surgery plus ICMT, surgery plus CCMT and RT, and surgery plus ICMT and RT were 8.9, 13.4, 23.7, 37.4, 48.3, and 68.5%, respectively. When taking into consideration the extent of tumor resection (n = 462), GTR followed by RT, CCMT, intrathecal chemotherapy, and high-dose chemotherapy provided the best OS (5-year OS 88.2%). In younger children, adjuvant ICMT had a greater 3-year OS than adjuvant RT alone (34.0% vs 0%, p = .001). This study identified independent favorable predictors for OS of ATRTs and distinguished significantly different OS following various treatment modalities. If tolerable, intensive treatment with GTR followed by adjuvant RT and ICMT is recommended. Intensified CCMT could be an alternative to avoid radiological radiotoxicity for younger children CRD42018098841.

Identifiants

pubmed: 30535934
doi: 10.1007/s10143-018-1055-9
pii: 10.1007/s10143-018-1055-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

281-292

Références

Cancer. 2010 Dec 15;116(24):5725-32
pubmed: 20737418
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43
pubmed: 16406394
J Neurooncol. 2009 Apr;92(2):177-83
pubmed: 19048188
Pediatr Blood Cancer. 2010 Jan;54(1):35-40
pubmed: 19798737
Childs Nerv Syst. 2008 Mar;24(3):307-12
pubmed: 17876589
Cancer. 2017 Feb 15;123(4):682-687
pubmed: 27861763
Neurol Med Chir (Tokyo). 1999 Jul;39(7):510-7; discussion 517-8
pubmed: 10437379
Pediatr Neurol. 2014 Oct;51(4):515-21
pubmed: 25266614
Eur J Cancer. 2012 Feb;48(3):353-9
pubmed: 22023887
Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):114-20
pubmed: 23498870
Cancer. 2012 Aug 1;118(15):3812-21
pubmed: 22180295
J Neurooncol. 2015 Jan;121(2):389-97
pubmed: 25362544
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1143-52
pubmed: 25311260
Pathology. 2016 Oct;48(6):555-63
pubmed: 27558890
J Clin Oncol. 2009 Jan 20;27(3):385-9
pubmed: 19064966
Cancer. 2012 Sep 1;118(17):4212-9
pubmed: 22213196
Am J Surg Pathol. 1998 Sep;22(9):1083-92
pubmed: 9737241
Neuro Oncol. 2014 Oct;16(10):1392-9
pubmed: 24847086
Klin Padiatr. 1998 Jul-Aug;210(4):227-33
pubmed: 9743957
J Neurooncol. 2012 Apr;107(2):413-9
pubmed: 22134767
Cancer Med. 2014 Feb;3(1):91-100
pubmed: 24402832
Acta Neurochir (Wien). 2015 Apr;157(4):589-96
pubmed: 25646852
J Neurosurg. 1996 Jul;85(1):56-65
pubmed: 8683283
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1756-63
pubmed: 21601374
Pediatr Blood Cancer. 2014 Jan;61(1):95-101
pubmed: 23934933
Front Oncol. 2012 Sep 12;2:114
pubmed: 22988546
Pediatr Blood Cancer. 2008 Aug;51(2):235-40
pubmed: 18381756
Childs Nerv Syst. 2018 Apr;34(4):627-638
pubmed: 29218405
J Pediatr Hematol Oncol. 1995 Feb;17(1):71-5
pubmed: 7743242
J Korean Med Sci. 2012 Feb;27(2):135-40
pubmed: 22323859
J Pediatr Hematol Oncol. 2009 Sep;31(9):651-63
pubmed: 19707161
J Clin Oncol. 2004 Jul 15;22(14):2877-84
pubmed: 15254056
J Pediatr Hematol Oncol. 2010 Jul;32(5):e182-6
pubmed: 20495479
J Neurooncol. 2016 Jan;126(1):81-90
pubmed: 26608522
J Neurooncol. 2010 May;98(1):117-23
pubmed: 19936623
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Pediatr Blood Cancer. 2011 Dec 1;57(6):978-85
pubmed: 21796761
Bone Marrow Transplant. 2014 Mar;49(3):370-5
pubmed: 24419520
Am J Surg Pathol. 2006 Nov;30(11):1462-8
pubmed: 17063089

Auteurs

Xiu-Jian Ma (XJ)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Tiantan Xili 6, Dongcheng District, Beijing, People's Republic of China.

Da Li (D)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Tiantan Xili 6, Dongcheng District, Beijing, People's Republic of China. lidaatlas@aliyun.com.

Liang Wang (L)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Tiantan Xili 6, Dongcheng District, Beijing, People's Republic of China.

Shu-Yu Hao (SY)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Tiantan Xili 6, Dongcheng District, Beijing, People's Republic of China.

Li-Wei Zhang (LW)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Tiantan Xili 6, Dongcheng District, Beijing, People's Republic of China.

Jun-Ting Zhang (JT)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Tiantan Xili 6, Dongcheng District, Beijing, People's Republic of China.

Zhen Wu (Z)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Tiantan Xili 6, Dongcheng District, Beijing, People's Republic of China. wz_ttyy@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH